Pharmaron Beijing Co., Ltd.

OTCPK:PHBB.F Stock Report

Market Cap: US$4.7b

Pharmaron Beijing Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Boliang Lou

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentage95.11%
CEO tenure7.8yrs
CEO ownershipn/a
Management average tenure7.8yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Boliang Lou's remuneration changed compared to Pharmaron Beijing's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

CN¥1b

Dec 31 2023CN¥2mCN¥2m

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥1b

Jan 01 2023n/an/a

CN¥1b

Sep 30 2022n/an/a

CN¥2b

Jun 30 2022n/an/a

CN¥2b

Mar 31 2022n/an/a

CN¥2b

Dec 31 2021CN¥8mCN¥2m

CN¥2b

Sep 30 2021n/an/a

CN¥1b

Jun 30 2021n/an/a

CN¥1b

Mar 31 2021n/an/a

CN¥1b

Dec 31 2020CN¥4mCN¥2m

CN¥1b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥865m

Mar 31 2020n/an/a

CN¥594m

Dec 31 2019CN¥3mCN¥2m

CN¥547m

Sep 30 2019n/an/a

CN¥437m

Jun 30 2019n/an/a

CN¥378m

Mar 31 2019n/an/a

CN¥346m

Dec 31 2018CN¥3mCN¥2m

CN¥333m

Compensation vs Market: Boliang's total compensation ($USD308.12K) is below average for companies of similar size in the US market ($USD6.86M).

Compensation vs Earnings: Boliang's compensation has been consistent with company performance over the past year.

CEO

Boliang Lou (61 yo)

7.8yrs
Tenure
CN¥2,208,000
Compensation

Dr. Boliang Lou, Ph D serves as Chairman of the Board and Chief Executive Officer at Pharmaron, Inc. He is a Co-Founder at Pharmaron, Inc. Dr. Lou serves as the Chairman, Chief Executive Officer and Manage...

Leadership Team

NamePositionTenureCompensationOwnership
Boliang Lou
Chairman & CEOno dataCN¥2.21mno data
Xiaoqiang Lou
Co-Founder7.8yrsCN¥1.91m5.66%
$ 264.7m
Bei Zheng
Executive VP & Executive Director7.8yrsCN¥1.60m2.12%
$ 99.1m
Shing Chung Li
CFO & Secretary of the Boardno dataCN¥1.96mno data
Hua Yang
Chief Scientific Officer & Deputy Manager7.8yrsCN¥1.85mno data
Connie Sun
Senior VP & Global Head of Business Development of Small Moleculesno datano datano data
Celina Zhong
Senior Vice President of Human Resourcesno datano datano data
Katherine Lee
Chief Business Officer13.6yrsno datano data
Stephen Lewinton
Senior Vice President of UK Operationsno datano datano data
Jingqi Huang
Senior Vice President of In Vivo Pharmacologyno datano datano data
Mandy Xu
Senior Vice President of DMPK2.7yrsno datano data
Sid Bhoopathy
Senior VP and US Head of Laboratory Services & CGT2.8yrsno datano data
7.8yrs
Average Tenure
57yo
Average Age

Experienced Management: PHBB.F's management team is seasoned and experienced (7.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Boliang Lou
Chairman & CEO7.8yrsCN¥2.21mno data
Xiaoqiang Lou
Co-Founder7.8yrsCN¥1.91m5.66%
$ 264.7m
Bei Zheng
Executive VP & Executive Director7.8yrsCN¥1.60m2.12%
$ 99.1m
Kexin Yang
Chairman of the Supervisory Committee7.8yrsno datano data
Jiaqing Li
Non Executive Director7.8yrsno datano data
Baifeng Hu
Non Executive Director6.8yrsno datano data
Kwan Hung Tsang
Independent Non Executive Director4.8yrsCN¥300.00kno data
Lan Zhang
Employee Representative Supervisor7.8yrsno datano data
Lihua Li
Independent Non Executive Director1.9yrsCN¥300.00k0.0042%
$ 197.3k
Jian Yu
Independent Non Executive Director4.1yrsCN¥300.00kno data
Shu Feng
Supervisor3.7yrsno datano data
Qilin Zhou
Independent Non-Executive Director1.9yrsCN¥300.00kno data
7.3yrs
Average Tenure
56.5yo
Average Age

Experienced Board: PHBB.F's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/11 22:04
End of Day Share Price 2024/05/14 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmaron Beijing Co., Ltd. is covered by 24 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Pei ChengChina Galaxy Securities Co., Ltd.
Jin ZhangChina International Capital Corporation Limited